Author:
Imberti Davide,Marietta Marco,Polo Friz Hernan,Cimminiello Claudio
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S–47S. doi:
10.1378/chest.1412S3
.
2. Harenberg J, Walenga J, Torri G, Subcommittee on Control of Anticoagulation, Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, et al. Update of the recommendations on biosimilar low-molecular-weight heparins from the scientific Subcommittee on Control of Anticoagulation of the International Society on thrombosis and Haemostasis. J Thromb Haemost. 2013;11(7):1421–5.
3. Harenberg J, Cimminiello C, Agnelli G, et al. Biosimilars of low-molecular-weight heparin products: fostering competition or reducing ‘biodiversity’? J Thromb Haemost. 2016;14(3):421–6. doi:
10.1111/jth.13237
. Epub 2016 Jan 30
4. Harenberg J. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization. Clin Appl Thromb Hemost. 2011;17(6):E158–64. doi:
10.1177/1076029610392216
. Epub 2011 Mar 14
5. Guidelines on clinical and non-clinical development of medicinal products containing low-molecular-weight heparins. European Medical Agency. EMEA/CHMP/BMWP/118264/2007.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003927.pdf
. Accessed 2 Dec 2016.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献